2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial
This study is registered with ClinicalTrials.gov, number NCT00427193.FindingsFrom May 8, 2007, to Feb 26, 2010, of 238 participants that were assessed, 218 were randomly assigned to and started a 25% calorie restriction diet (n=143, 66%) or an ad libitum control diet (n=75, 34%). Individuals in the calorie restriction group achieved a mean reduction in calorie intake of 11·9% (SE 0·7; from 2467 kcal to 2170 kcal) versus 0·8% (1·0) in the control group, and a sustained mean weight reduction of 7·5 kg (SE 0·4) versus an increase of 0·1 kg (0·5) in the control group, of ...
Source: The Lancet Diabetes and Endocrinology - July 13, 2019 Category: Endocrinology Source Type: research

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
Publication date: Available online 10 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ian J Neeland, Robert Ross, Jean-Pierre Després, Yuji Matsuzawa, Shizuya Yamashita, Iris Shai, Jaap Seidell, Paolo Magni, Raul D Santos, Benoit Arsenault, Ada Cuevas, Frank B Hu, Bruce Griffin, Alberto Zambon, Philip Barter, Jean-Charles Fruchart, Robert H Eckel, International Atherosclerosis Society, International Chair on Cardiometabolic Risk Working Group on Visceral ObesitySummaryFindings from epidemiological studies over the past 30 years have shown that visceral adipose tissue, accurately measured by CT or ...
Source: The Lancet Diabetes and Endocrinology - July 11, 2019 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2019; published online July 8. http://dx.doi.org/10.1016/S2213-8587(19)30158-5
Publication date: Available online 8 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 10, 2019 Category: Endocrinology Source Type: research

Baby foods: time to get tough on sugars
Publication date: Available online 3 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 4, 2019 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2019; 7: 356–67
Publication date: Available online 1 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 2, 2019 Category: Endocrinology Source Type: research

More aggressive lipid lowering in people with diabetes?
Publication date: Available online 1 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Frederick J Raal, Farzahna Mohamed (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 2, 2019 Category: Endocrinology Source Type: research

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Publication date: Available online 1 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L Bhatt, Vera A Bittner, Andrzej J Budaj, Rafael Diaz, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Virginie Loizeau, Renato D Lopes, Angèle Moryusef, Jan Murin, Robert Pordy, Arsen D Ristic, Matthew T Roe, José TuñónSummaryBackgroundAfter acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1&middo...
Source: The Lancet Diabetes and Endocrinology - July 2, 2019 Category: Endocrinology Source Type: research

Maternal thyroid function during pregnancy and child brain morphology: a time window-specific analysis of a prospective cohort
Publication date: Available online 28 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Toyah A Jansen, Tim I M Korevaar, Tessa A Mulder, Tonya White, Ryan L Muetzel, Robin P Peeters, Henning TiemeierSummaryBackgroundAdequate thyroid hormone availability during pregnancy is necessary for optimal fetal brain development. During the first 18–20 weeks of gestation, fetal thyroid hormone availability largely depends on the placental transfer of maternal thyroxine. Although various studies have shown that maternal thyroid dysfunction is associated with suboptimal child neurodevelopmental outcomes, the mos...
Source: The Lancet Diabetes and Endocrinology - June 29, 2019 Category: Endocrinology Source Type: research

Maternal thyroid function and brain development: time for preconception screening?
Publication date: Available online 28 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Francesco Vermiglio, Mariacarla Moleti (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 29, 2019 Category: Endocrinology Source Type: research

The role of blood volume in cardiac dysfunction and reduced exercise tolerance in patients with diabetes
Publication date: Available online 26 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): David Montero, Candela Diaz-Canestro, Laura Oberholzer, Carsten LundbySummaryBlood volume is an integral component of the cardiovascular system, and fundamental to discerning the pathophysiology of multiple cardiovascular conditions leading to exercise intolerance. Based on a systematic search of controlled studies assessing blood volume, in this Personal View we describe how hypovolaemia is a prevalent characteristic of patients with diabetes, irrespective of sex, age, and physical activity levels. Multiple endocrine a...
Source: The Lancet Diabetes and Endocrinology - June 28, 2019 Category: Endocrinology Source Type: research

Shrinkage of pituitary adenomas with pasireotide
Publication date: July 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 7Author(s): Adrian F Daly, Iulia Potorac, Patrick Petrossians, Albert Beckers (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 20, 2019 Category: Endocrinology Source Type: research

Shrinkage of pituitary adenomas with pasireotide – Authors' reply
Publication date: July 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 7Author(s): Eva C Coopmans, Aart J van der Lely, Joppe J Schneiders, Sebastian J C M M Neggers (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 20, 2019 Category: Endocrinology Source Type: research

Response to editorial expression of concern
Publication date: July 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 7Author(s): Nicolas Vodovar, Hélène Nougué, Jean-Marie Launay, Alain Cohen Solal, Damien Logeart (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 20, 2019 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2019; 7: 560–74
Publication date: July 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 7Author(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 20, 2019 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2017; 5: 495–96
Publication date: July 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 7Author(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 20, 2019 Category: Endocrinology Source Type: research

Research in brief
Publication date: July 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 7Author(s): Kate V McIntosh (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 20, 2019 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2019; 7: 417–19
Publication date: Available online 17 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 19, 2019 Category: Endocrinology Source Type: research

Amos Laar: combating non-communicable diseases in Ghana
Publication date: Available online 12 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ray Cavanaugh (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 13, 2019 Category: Endocrinology Source Type: research

The expanding résumé of SGLT2 inhibitors
Publication date: Available online 10 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ian H de Boer (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 11, 2019 Category: Endocrinology Source Type: research

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
Publication date: Available online 10 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Eri T Kato, Ingrid A M Gause-Nilsson, Martin Fredriksson, Peter A Johansson, Anna Maria Langkilde, Marc S SabatineSummaryBackgroundSodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic cardio...
Source: The Lancet Diabetes and Endocrinology - June 11, 2019 Category: Endocrinology Source Type: research

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
This study is registered with ClinicalTrials.gov, number NCT02501161.FindingsFrom Jan 8, 2016, to Oct 3, 2018, 1345 patients were screened, of which 1012 (75·2%) were eligible and randomly assigned to either IDegLira (n=506) or IGlar U100 (n=506). 484 (96%) of 506 in the IDegLira group and 481 (95%) of 506 in the IGlar U100 group completed the trial. Baseline characteristics were similar and representative of patients eligible for basal insulin intensification (overall mean diabetes duration 10 years; HbA1c 8·5% [69 mmol/mol]; fasting plasma glucose 10 mmol/L). Patients in the IDegLira group had significantly...
Source: The Lancet Diabetes and Endocrinology - June 10, 2019 Category: Endocrinology Source Type: research

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Publication date: Available online 9 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, Jan W Eriksson, Simon Heller, Ole Holm Hels, Richard Pratley, Thozhukat Sathyapalan, Cyrus Desouza, R Abramof, D Alpenidze, S Aronoff, K Astamirova, B Barker, G Bedel, L Belousova, M Benson, I Beshay, W Biggs, K BlazeSummaryBackgroundOral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We ai...
Source: The Lancet Diabetes and Endocrinology - June 10, 2019 Category: Endocrinology Source Type: research

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
Publication date: Available online 9 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Thomas R Pieber, Bruce Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Signe O R Wallenstein, John B Buse, S Akın, N Aladağ, A A Arif, L J Aronne, S Aronoff, E Ataoglu, S H Baik, H Bays, P L Beckett, D Berker, S Bilz, B BodeSummaryBackgroundOral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglutide with sitagliptin 1...
Source: The Lancet Diabetes and Endocrinology - June 10, 2019 Category: Endocrinology Source Type: research

IDegLira: combining efficacy, durability, and convenience?
Publication date: Available online 9 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Srikanth Bellary, Abd A Tahrani, Anthony H Barnett (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 10, 2019 Category: Endocrinology Source Type: research

Pioneering oral peptide therapy for patients with type 2 diabetes
Publication date: Available online 9 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Michael A Nauck, Juris J Meier (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 10, 2019 Category: Endocrinology Source Type: research

Diabetes in humanitarian crises: the Boston Declaration
Publication date: Available online 6 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Sylvia Kehlenbrink, Lindsay M Jaacks, Sigiriya Aebischer Perone, Éimhín Ansbro, Elizabeth Ashbourne, Carol Atkinson, Mark Atkinson, Rifat Atun, Stéphane Besançon, Philippa Boulle, Helen Bygrave, Enrique Caballero, Katy Cooper, Angelica Cristello, Katy Digovich, Shannon Doocy, Senan Ebrahim, Margaret Ewen, Dina Goodman, Lena Hamvas (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 7, 2019 Category: Endocrinology Source Type: research

Celebrating uniqueness in endocrinology and sport
Publication date: Available online 6 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 7, 2019 Category: Endocrinology Source Type: research

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial
Publication date: Available online 4 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Alexander Dimitri Miras, Belén Pérez-Pevida, Madhawi Aldhwayan, Anna Kamocka, Emma Rose McGlone, Werd Al-Najim, Harvinder Chahal, Rachel L Batterham, Barbara McGowan, Omar Khan, Veronica Greener, Ahmed R Ahmed, Aviva Petrie, Samantha Scholtz, Stephen R Bloom, Tricia M TanSummaryBackgroundMany patients with type 2 diabetes do not achieve sustained diabetes remission after metabolic (bariatric) surgery for the treatment of obesity. Liraglutide, a glucagon-like peptide-1 analogue, improves glycaemic control an...
Source: The Lancet Diabetes and Endocrinology - June 5, 2019 Category: Endocrinology Source Type: research

Treatment of persistent or recurrent type 2 diabetes after metabolic surgery
Publication date: Available online 4 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Geltrude Mingrone (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 5, 2019 Category: Endocrinology Source Type: research

Three generational phenotypes of sporadic primary hyperparathyroidism: evolution defined by technology
Publication date: Available online 3 June 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Cristiana Cipriani, John P Bilezikian (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - June 4, 2019 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2019; published online May 13. https://doi.org/10.1016/S2213-8587(19)30076-2
Publication date: Available online 22 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 23, 2019 Category: Endocrinology Source Type: research

Diabetes in pregnancy and epigenetic mechanisms—how the first 9 months from conception might affect the child's epigenome and later risk of disease
Publication date: Available online 22 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Line Hjort, Boris Novakovic, Louise G Grunnet, Louise Maple-Brown, Peter Damm, Gernot Desoye, Richard SafferySummaryDiabetes in pregnancy is not only associated with increased risk of pregnancy complications and subsequent maternal metabolic disease, but also increases the risk of long-term metabolic disease in the offspring. At the interface between genetic and environmental factors, epigenetic variation established in utero represents a plausible link between the in utero environment and later disease susceptibility. T...
Source: The Lancet Diabetes and Endocrinology - May 23, 2019 Category: Endocrinology Source Type: research

Sicker, Fatter, Poorer: The Urgent Threat of Hormone-Disrupting Chemicals to Our Health and Future…and What We Can Do About It, Leonardo Trasande. Houghton Mifflin Harcourt (2019), 240, US$22·00, ISBN: 978-1328553492
Publication date: Available online 16 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Michele A La Merrill (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 17, 2019 Category: Endocrinology Source Type: research

Nutrition, weight loss, and type 2 diabetes
Publication date: June 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 6Author(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 17, 2019 Category: Endocrinology Source Type: research

Insulin resistance underlying type 2 diabetes
Publication date: June 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 6Author(s): Luís Maurício T R Lima (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 17, 2019 Category: Endocrinology Source Type: research

Insulin resistance underlying type 2 diabetes – Authors' reply
Publication date: June 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 6Author(s): Maria I Schmidt, Paula A Bracco, Bruce B Duncan (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 17, 2019 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2019; 7: 385–96
Publication date: June 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 6Author(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 17, 2019 Category: Endocrinology Source Type: research

Research digest: SGLT2 inhibition in kidney and liver disease
Publication date: June 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 6Author(s): David Preiss, Naveed Sattar (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 17, 2019 Category: Endocrinology Source Type: research

Understanding the mechanisms of reversal of type 2 diabetes
Publication date: Available online 13 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Roy Taylor, Ahmad Al-Mrabeh, Naveed SattarSummaryClinical and pathophysiological studies have shown type 2 diabetes to be a condition mainly caused by excess, yet reversible, fat accumulation in the liver and pancreas. Within the liver, excess fat worsens hepatic responsiveness to insulin, leading to increased glucose production. Within the pancreas, the β cell seems to enter a survival mode and fails to function because of the fat-induced metabolic stress. Removal of excess fat from these organs via substantial wei...
Source: The Lancet Diabetes and Endocrinology - May 14, 2019 Category: Endocrinology Source Type: research

Sugar and Tension: Diabetes and Gender in Modern India, Lesley Jo Weaver. Rutgers University Press (2018), 202, US$34·95, ISBN: 978-1-9788-0300-8
Publication date: Available online 10 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Latha Palaniappan (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 12, 2019 Category: Endocrinology Source Type: research

Dietary transitions and cardiometabolic health in China
Publication date: Available online 10 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Xiong-Fei Pan, An Pan (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 12, 2019 Category: Endocrinology Source Type: research

The dietary transition and its association with cardiometabolic mortality among Chinese adults, 1982–2012: a cross-sectional population-based study
Publication date: Available online 10 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Yuna He, Yanping Li, Xiaoguang Yang, Elena C Hemler, Yuehui Fang, Liyun Zhao, Jian Zhang, Zhenyu Yang, Zhu Wang, Li He, Jing Sun, Dong D Wang, Jingzhong Wang, Jianhua Piao, Xiaofeng Liang, Gangqiang Ding, Frank B HuSummaryBackgroundFew studies have used nationally representative data to describe dietary trends and the related cardiometabolic mortality burden in China. Thus, we aimed to characterise the trends in disease-related dietary factors as well as their associated disease burden among Chinese adults from 1982 to 2...
Source: The Lancet Diabetes and Endocrinology - May 12, 2019 Category: Endocrinology Source Type: research

Sophia Zoungas: clinician, researcher, and full-time mum
Publication date: Available online 9 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Tony Kirby (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 11, 2019 Category: Endocrinology Source Type: research

The importance of high-quality mendelian randomisation studies for clinical thyroidology
Publication date: Available online 7 May 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marco Medici, Robin Peeters, Alexander Teumer, Peter Taylor (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 8, 2019 Category: Endocrinology Source Type: research

Predicting individual treatment response in diabetes
Publication date: Available online 29 April 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Hiddo J L Heerspink (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 30, 2019 Category: Endocrinology Source Type: research

Continuous glucose monitoring-based technologies in hypoglycaemia-prone patients with type 1 diabetes
Publication date: Available online 29 April 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Norbert Hermanns, Dominic Ehrmann, Bernhard Kulzer (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 30, 2019 Category: Endocrinology Source Type: research

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
Publication date: Available online 29 April 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): John M Dennis, Beverley M Shields, William E Henley, Angus G Jones, Andrew T HattersleySummaryBackgroundResearch using data-driven cluster analysis has proposed five subgroups of diabetes with differences in diabetes progression and risk of complications. We aimed to compare the clinical utility of this subgroup-based approach for predicting patient outcomes with an alternative strategy of developing models for each outcome using simple patient characteristics.MethodsWe identified five clusters in the ADOPT trial (n=43...
Source: The Lancet Diabetes and Endocrinology - April 30, 2019 Category: Endocrinology Source Type: research

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial
Publication date: Available online 29 April 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Emanuele Bosi, Pratik Choudhary, Harold W de Valk, Sandrine Lablanche, Javier Castañeda, Simona de Portu, Julien Da Silva, Roseline Ré, Linda Vorrink-de Groot, John Shin, Francine R Kaufman, Ohad Cohen, SMILE Study GroupSummaryBackgroundHypoglycaemia unawareness and severe hypoglycaemia can increase fear of hypoglycaemia and the risk of subsequent hypoglycaemic events. We aimed to assess the safety and efficacy of insulin pump therapy with integrated continuous glucose monitoring (CGM) and a suspend-befor...
Source: The Lancet Diabetes and Endocrinology - April 30, 2019 Category: Endocrinology Source Type: research

Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study
Publication date: Available online 26 April 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Qiuhong Gong, Ping Zhang, Jinping Wang, Jixiang Ma, Yali An, Yanyan Chen, Bo Zhang, Xinxing Feng, Hui Li, Xiaoping Chen, Yiling J Cheng, Edward W Gregg, Yinghua Hu, Peter H Bennett, Guangwei Li, Xin Qian, Lihong Zhang, Yuanchi Hui, Siyao He, Xuan WangSummaryBackgroundLifestyle interventions can delay the onset of type 2 diabetes in people with impaired glucose tolerance, but whether this leads subsequently to fewer complications or to increased longevity is uncertain. We aimed to assess the long-term effects of lifesty...
Source: The Lancet Diabetes and Endocrinology - April 27, 2019 Category: Endocrinology Source Type: research

Da Qing 30 years on: more reasons to extend diabetes prevention
Publication date: Available online 25 April 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Michael E J Lean, Naveed Sattar (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 27, 2019 Category: Endocrinology Source Type: research